Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Clinical Imbalances

Hormonal

Modifiable Lifestyle Factors

Diet

Laboratory Testing

Blood

Text Availability

Abstract

201

Full text

178

Free full text

Publication Types

Journal Article

202

Research Support, Non-U.S. Gov't

112

Randomized Controlled Trial

Review

Comparative Study

Multicenter Study

Clinical Trial

Observational Study

Clinical Trial, Phase III

Systematic Review

Research Support, N.I.H., Extramural

Meta-Analysis

Letter

Controlled Clinical Trial

Comment

Case Reports

Evaluation Study

Research Support, U.S. Gov't, Non-P.H.S.

Historical Article

Network Meta-Analysis

Clinical Trial Protocol

Publication Year

From

Quick links

Individual year

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2000

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Insulin, Long-Acting""[mesh_terms]

205 Results

Searching titles within these results

Long-Acting Insulin on the Road to Recovery With Diabetic Ketoacidosis.

Margo Halm, Sandra Bunn

American journal of critical care : an official publication, American Association of Critical-Care Nurses 2018;25(3):277-80

Full Text

Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes.

Stewart Harris, Martin J Abrahamson, Antonio Ceriello, Guillaume Charpentier, Marc Evans, Roger Lehmann, Andreas Liebl, Sultan Linjawi, Richard I G Holt, Nóra Hosszúfalusi, Guy Rutten, Tina Vilsbøll

Drugs 2020;80(2):147-165

Free Full Text

Abstract

Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing.

Anne Lützen, Niels Rode Kristensen, Thomas Kjeldsen, František Hubálek, Bo Falk Hansen, Tine Glendorf, Lone Pridal, Erica Nishimura, Karsten Lyby, Hanne Haahr, Carsten Enggaard Stidsen, Rasmus Ribel-Madsen, Thomas Åskov Pedersen, Peter Madsen

BMJ open diabetes research & care 2021;9(1):e002301

Free Full Text

Abstract

Optimization of a Coupling Process for Insulin Degludec According to a Quality by Design (QbD) Paradigm.

Lei Nie, Mingming Hu, Xu Yan, Tingting Guo, Haibin Wang, Sheng Zhang, Haibin Qu

AAPS PharmSciTech 2018;19(5):2185-2194

Full Text

Abstract

Switching basal insulins in type 2 diabetes: practical recommendations for health care providers.

Robert J Tanenberg, John E Anderson, Jennifer M Trujillo, Sarah L Anderson

Postgraduate medicine 2018;130(2):229-238

Full Text

Abstract

Basal insulin therapy in type 2 diabetes.

M Angelyn Bethel, Mark N Feinglos

The Journal of the American Board of Family Practice 2005;18(3):199-204

Free Full Text

Abstract

Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: advances in clinical research.

Manuel Muñoz Torres

Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 2015;61(3):153-9

Full Text

Abstract

Basal plus basal-bolus approach in type 2 diabetes.

Paolo Rossetti, F Javier Ampudia-Blasco, Juan F Ascaso

Diabetes technology & therapeutics 2011;13 Suppl 1():S75-83

Free Full Text

Abstract

Pre-Basal Insulin Analog Era: Paving the Way for Modern Day Basal Insulins.

Viswanathan Mohan, Dipanjan Bhattacharjee, Ashwin Karuppan, B Karthik, Nilakshi Deka, L Sreenivasamurthy, Rajesh Khadgawat, Prasun Deb, Mangesh Tiwaskar

The Journal of the Association of Physicians of India 2020;68(12[Special]):9-12

Full Text

Abstract

Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs.

Régis P Radermecker, André J Scheen, Gérald E Piérard

American journal of clinical dermatology 2007;8(1):21-8

Full Text

Abstract

Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines.

Roopa Mehta, Roger Chen, Takahisa Hirose, Mathew John, Adri Kok, Roger Lehmann, Ambika Gopalakrishnan Unnikrishnan, Dilek Gogas Yavuz, Gregory Fulcher

Diabetes, obesity & metabolism 2021;22(11):1961-1975

Free Full Text

Abstract

Optimizing the replacement of basal insulin in type 1 diabetes mellitus: no longer an elusive goal in the post-NPH era.

Anna Marinelli Andreoli, Geremia B Bolli, Paola Lucidi

Diabetes technology & therapeutics 2011;13 Suppl 1():S43-52

Free Full Text

Abstract

A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice.

Giorgio Sesti, Lars Bardtrum, Selcuk Dagdelen, Natalie Halladin, Martin Haluzík, Petra Őrsy, Martin Rodríguez, Vanita R Aroda

Diabetes, obesity & metabolism 2021;22(5):873-878

Free Full Text

Abstract

Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial.

Olof Asplund, Hertzel Gerstein, Guillaume Paré, Leif Groop, Maria F Gomez, Sibylle Hess, Marie Pigeyre

Diabetologia 2022;65(1):206-215

Full Text

Abstract

Subcutaneous fast-acting insulin analogues ± long-acting insulin vs IV insulin infusion in DKA: updated meta-analysis of randomised trials.

Beng Leong Lim, Kee Vooi Loo, Yan Ee Lynette Chung, Berlin Lee, Wei Feng Lee

Endocrine 2025;87(3):920-932

Full Text

Abstract

Results: 1 – 15 / 205

Filters

Expert Opinion

Clinical Imbalances

Modifiable Lifestyle Factors

Laboratory Testing

Text Availability

Publication Types

Publication Year

Results for ""Insulin, Long-Acting""[mesh_terms]

Long-Acting Insulin on the Road to Recovery With Diabetic Ketoacidosis.

Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes.

Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing.

Optimization of a Coupling Process for Insulin Degludec According to a Quality by Design (QbD) Paradigm.

Switching basal insulins in type 2 diabetes: practical recommendations for health care providers.

Basal insulin therapy in type 2 diabetes.

Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: advances in clinical research.

Basal plus basal-bolus approach in type 2 diabetes.

Pre-Basal Insulin Analog Era: Paving the Way for Modern Day Basal Insulins.

Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs.

Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines.

Optimizing the replacement of basal insulin in type 1 diabetes mellitus: no longer an elusive goal in the post-NPH era.

A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice.

Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial.

Subcutaneous fast-acting insulin analogues ± long-acting insulin vs IV insulin infusion in DKA: updated meta-analysis of randomised trials.

Results for
""Insulin, Long-Acting""[mesh_terms]